The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

SPRAVATO has been increasing in sales for the last several quarters, and I believe last year it was the fastest growing product in Janssen's portfolio. Did we hit a billion in sales last year?

according to J&J's pharma unit Janssen. Maintaining remission at 32 weeks was a key secondary endpoint, hit by 55% of the Spravato group and 37% of patients taking quetiapine, with the proportion ...

And in for Spravato, we have 63 of our clinics that ... But it's our intention to leverage our distribution partners. And right now, Janssen does make their distributors offer 120-day terms.

Janssen (Johnson & Johnson ... legal difficulties regarding the insurance coverage surrounding the use of Spravato as a treatment for her patients, which was approved by the FDA.

One recent novel addition to the treatment toolbox for TRD is esketamine nasal spray (Spravato), which has been ... consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics ...

On January 21, JNJ’s subsidiary, Janssen-Cilag International NV announced the European ... JNJ announced the U.S. FDA approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® (esketamine) ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...